# BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment

> **NCT02326844** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 3 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** BMN 673 (talazoparib)

## Key facts

- **NCT ID:** NCT02326844
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-03-02
- **Primary completion:** 2016-04-14
- **Final completion:** 2016-04-14
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Study was closed by the Cancer Therapy Evaluation Program (CTEP)
- **Last updated:** 2020-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02326844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02326844, "BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02326844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*